4.7 Review

Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma

期刊

BIOMEDICINES
卷 9, 期 2, 页码 -

出版社

MDPI
DOI: 10.3390/biomedicines9020178

关键词

pancreatic cancer; pancreatic ductal adenocarcinoma; stem cells; pancreatic cancer stem cells

资金

  1. Stem Centric Co. Ltd., Korea

向作者/读者索取更多资源

Pancreatic cancer is a severe and devastating disease, with the main factor contributing to tumor development and resistance being pancreatic cancer stem cells (PCSCs). Stem cells, particularly mesenchymal stem cells (MSCs), are considered influential anti-cancer agents that control the pancreatic tumor microenvironment through anti-inflammatory actions and activation of host immune cells.
One of the most severe and devastating cancer is pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is one of the major pancreatic exocrine cancer with a poor prognosis and growing prevalence. It is the most deadly disease, with an overall five-year survival rate of 6% to 10%. According to various reports, it has been demonstrated that pancreatic cancer stem cells (PCSCs) are the main factor responsible for the tumor development, proliferation, resistance to anti-cancer drugs, and recurrence of tumors after surgery. PCSCs have encouraged new therapeutic methods to be explored that can specifically target cancer cells. Furthermore, stem cells, especially mesenchymal stem cells (MSCs), are known as influential anti-cancer agents as they function through anti-inflammatory, paracrine, cytokines, and chemokine's action. The properties of MSCs, such as migration to the site of infection and host immune cell activation by its secretome, seem to control the microenvironment of the pancreatic tumor. MSCs secretome exhibits similar therapeutic advantages as a conventional cell-based therapy. Moreover, the potential for drug delivery could be enhanced by engineered MSCs to increase drug bioactivity and absorption at the tumor site. In this review, we have discussed available therapeutic strategies, treatment hurdles, and the role of different factors such as PCSCs, cysteine, GPCR, PKM2, signaling pathways, immunotherapy, and NK-based therapy in pancreatic cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据